News

Published on 2 Jan 2023 on Simply Wall St. via Yahoo Finance

Is There An Opportunity With MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) 28% Undervaluation?


Article preview image

Today we will run through one way of estimating the intrinsic value of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Believe it or not, it's not too difficult to follow, as you'll see from our example!

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Check out our latest analysis for MERCK Kommanditgesellschaft auf Aktien

PAR.MRK price evolution
XETRA.MRK price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest...

Insider Monkey · via Yahoo Finance 22 Nov 2024

The Zacks Analyst Blog Highlights Broadcom, Merck, Qualcomm and Natural Health

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks ...

Zacks · via Yahoo Finance 22 Nov 2024

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you mig...

Zacks · via Yahoo Finance 22 Nov 2024

Exclusive-US FDA finds widely used asthma drug impacts the brain

U.S. government researchers have found that a widely prescribed asthma drug originally sold by Me...

Reuters · via Yahoo Finance 22 Nov 2024

Merck Stock Trades Near 52-Week Low: What's Next for Investors?

Key Takeaways Merck's shares have lost 25.6% in the past six months compared with a decline of 11...

Zacks · via Yahoo Finance 21 Nov 2024

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) ...

Motley Fool · via Yahoo Finance 21 Nov 2024

Keytruda represents almost half of Merck’s sales, and a new formulation could...

A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stag...

Pharma Voice · via Yahoo Finance 21 Nov 2024

Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s...

We recently published a list of Ken Griffin Stock Portfolio: 10 Stocks to Buy. In this article, w...

Insider Monkey · via Yahoo Finance 20 Nov 2024

J&J, Merck Cut Jobs in China as Local Competition Takes Toll

Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition fro...

Bloomberg 20 Nov 2024

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin...

On Tuesday, Merck & Co Inc (NYSE:MRK) revealed topline results from the pivotal Phase 3 MK-3475A-...

Benzinga · via Yahoo Finance 19 Nov 2024